Struggling to Find Investors?

If you’re an inventor or a small R&D team lead, you’ve probably felt the same friction point again and again:

• You’ve got a real innovation.
• You can explain it.
• You can defend it technically.
• You may even have protection in place.

And yet the project keeps stalling at the same place:

“We just need the right investor.”

“We just need someone to back us.”

“We cant seem to get our first commercial deal”

That belief is understandable — but it’s also the reason so many strong projects don’t get momentum.

Because most early-stage projects don’t fail due to lack of innovation.

They fail because the team never solves the WHO.

Not the “who might invest if we pitch hard enough.”

The “who already has what we need — and can say yes because it strengthens their position.”

That is a completely different game.

And it’s the focus of my free live webinar on Tuesday January 27th 7:00 PM NYC time, and Wednesday 28 January 2026, In Australia and also in UK at 8:00am GMT. (choose the session that suits you).

Here’s your registration link: https://calendly.com/danielinperth/securing-commercial-partners

The hard truth: inventing is not commercialising

Inventors and R&D teams are trained to improve the product. That’s what you’re good at.

So when the market doesn’t respond fast enough, the default move is predictable:

• “Let’s build a better version.”
• “Let’s add features.”
• “Let’s spend more on engineering.”
• “Let’s tighten the prototype.”

And you can do that forever.

But commercial traction doesn’t come from technical perfection. It comes from commercial structure — and structure starts with the right party across the table.

In early-stage commercialisation, your biggest advantage is not a bigger patent or a longer pitch deck.

It’s choosing a WHO that already has:

• a channel
• a customer base
• manufacturing capability
• regulatory approvals
• installation teams
• salespeople
• credibility
• existing demand
• service infrastructure
• or a strategic reason to move now

When you solve the WHO, the project starts to move even if the product is still “version one”.

Why “investor-first” is usually the slowest path

Most inventors go investor-first because it feels logical:

1. Raise money
2. Build product
3. Scale
4. Win

But investor-first often forces you into the most difficult scenario:

• You’re asking someone to take risk without control
• You’re asking them to fund an outcome they can’t personally execute
• You’re asking for money before you’ve reduced risk

That leads to months of pitching, rejection, delays, and self-doubt.

Now compare that to a partner-first approach:

• You’re offering a strategic player a way to gain advantage
• You’re offering them a deal where risk is reduced because they can execute internally
• You’re offering them value that’s aligned with what they’re already doing

That’s why I keep teaching the same principle:

The quickest path to cash-flow is usually not “find an investor.”

It’s “find a partner who can help create the first transaction.”

And the first transaction is what gives you momentum.

The four cash-generating transactions (and why they all start with WHO)

In my work with inventors and small R&D teams, we focus on four outcomes. Not twenty. Not “everything at once.”

Just four:

1. A modest capital raise (not a fantasy round — a practical one)
2. A distribution agreement
3. A licensing agreement
4. A trade sale pathway (even if staged later)

Here’s the key insight:

The “WHO” you choose often influences two, sometimes three, of these outcomes.

For example, the right partner might:

• distribute first,
• then license in a second geography,
• and later become the trade buyer — because you’ve built the relationship and the logic step-by-step.

This is why the WHO matters so much: it’s not just “someone to pitch to.” It’s the party around which your entire deal pathway can form.

The mistake that silently kills good projects: chasing the wrong WHO

Most people select prospects based on the wrong criteria:

• “They’re big.”
• “They have money.”
• “They’re famous.”
• “They’re in my industry.”
• “They might buy.”

But size and fame don’t equal fit.

The right WHO is selected based on criteria that are often unrelated to ROI headlines.

That’s why in this webinar I’ll unpack a selection method we use constantly:

The 10–4–1 selection method

• Start with 10 credible partner candidates (not 200 randoms)
• Qualify down to 4 that genuinely fit your commercial model
• Choose the 1 best first move and pursue it properly

This is not about mass outreach and hoping someone bites.

It’s about making your first approach so targeted, so de-risked, and so commercially clear that it becomes difficult to ignore.

“But what if they steal my idea?”

A fair fear — and also one of the most misunderstood.

Protection matters, but protection alone does not create traction.

And if you use protection as a reason to delay outreach, you can end up with a patented project that still goes nowhere.

Part of the WHO strategy is knowing how to move safely and fast:

• how to position the project without over-disclosure
• how to sequence information release
• how to use the right paperwork at the right stage
• how to build leverage before you ask for anything

In other words: you can move forward without being reckless.

Leverage: the thing that makes partners lean in

Most inventors think a deal is:

“Give me money and I’ll give you equity.”

That’s the simplest deal structure — and often the weakest.

In professional commercialisation, we look at leverages: things that make a partner’s decision easier because they can see what they gain that doesn’t cost you cash.

Examples of leverages (depending on the project) can include:

• access to a new segment they already want
• cost savings inside their operations
• faster install/service time
• reduced warranty exposure
• a new product line they can sell immediately
• differentiation against competitors
• speed-to-market advantage
• exclusivity by geography or demographic
• the ability to turn a sunk cost into a new revenue stream

Then we stack leverages so the partner sees the deal as commercially sensible, not speculative.

This is one of the reasons partners move faster than investors: partners can say “yes” because they can do something with it.

What you’ll walk away with from this

This isn’t a motivational session. It’s a practical session. If you attend live, you’ll come away with:

• clarity on which of the four transactions is your best “first move”
• a sharper definition of the WHO you should target first
• the selection criteria behind the 10–4–1 method
• a clear view of how leverage stacking reduces partner risk
• a way to stop “pitching at everyone” and start approaching strategically
• a path that creates momentum without waiting for perfect conditions

And you’ll also understand something that changes the way you operate going forward:

Your job is not to convince. Your job is to construct a deal environment where the right WHO can say yes.

That’s commercialisation.